Celldex Therapeutics (NASDAQ:CLDX) Stock Crosses Above 200-Day Moving Average – Should You Sell?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $24.38 and traded as high as $26.60. Celldex Therapeutics shares last traded at $26.03, with a volume of 491,410 shares traded.

Wall Street Analyst Weigh In

CLDX has been the topic of a number of recent research reports. Mizuho started coverage on Celldex Therapeutics in a report on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price objective on the stock. Barclays increased their price target on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $62.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.10.

Celldex Therapeutics Stock Performance

The firm has a 50-day moving average price of $26.22 and a 200 day moving average price of $24.43. The stock has a market capitalization of $1.80 billion, a P/E ratio of -8.04 and a beta of 1.13.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 33.22%. On average, equities analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Celldex Therapeutics news, insider Richard M. Wright sold 49,298 shares of the company’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the completion of the sale, the insider directly owned 20,833 shares in the company, valued at $499,992. This represents a 70.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 4.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors have recently bought and sold shares of the stock. Handelsbanken Fonder AB increased its stake in Celldex Therapeutics by 2.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 21,600 shares of the biopharmaceutical company’s stock worth $440,000 after purchasing an additional 500 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Celldex Therapeutics by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after buying an additional 680 shares during the last quarter. AlphaQuest LLC boosted its position in Celldex Therapeutics by 7.0% during the 2nd quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 844 shares during the period. Finally, Nisa Investment Advisors LLC grew its holdings in Celldex Therapeutics by 171.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 881 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.